| GrowGeneration Announces Second Quarter 2026 Earnings Release Conference Call for August 11, 2026 |
Globe Newswire |
07/28 |
08:00 |
| Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides |
Globe Newswire |
07/28 |
07:50 |
| Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial |
Globe Newswire |
07/28 |
07:47 |
| Implicity’s Next-Generation ILR ECG Analyzer Earns FDA Clearance |
Globe Newswire |
07/28 |
07:45 |
| ERAS INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - August 10, 2026 Deadline |
Globe Newswire |
07/28 |
07:45 |
| Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution |
Globe Newswire |
07/28 |
07:30 |
| ZenaTech’s ZenaDrone Begins Testing Phase for Interceptor P-1 Counter-UAS Drone Platform |
Globe Newswire |
07/28 |
07:30 |
| Hubbell Reports Second Quarter 2026 Results |
Globe Newswire |
07/28 |
07:30 |
| Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth |
Globe Newswire |
07/28 |
07:30 |
| Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer |
Globe Newswire |
07/28 |
07:30 |
| Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD) |
Globe Newswire |
07/28 |
07:30 |
| PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc. |
Globe Newswire |
07/28 |
07:30 |
| Judge Consulting Group President and CTO John Battaglia Named to City & State PA’s 2026 “40 in Their 40s” List |
Globe Newswire |
07/28 |
07:26 |
| DCX’s DexTrader Announces Upgrade, Targeting On-Chain Yield-Bearing Collateralized Derivatives Data Services Segment |
Globe Newswire |
07/28 |
07:18 |
| Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance |
Globe Newswire |
07/28 |
07:00 |
| Blue Gold Announces Appointment of Andrew Cavaghan as Chairman |
Globe Newswire |
07/28 |
07:00 |
| Westhaven Reports South Zone Resource Infill Drilling Continues to Confirm Continuity of High-Grade Gold and Silver Mineralization Including 27.51m Grading 14.47 g/t Au & 52 g/t Ag Shovelnose Gold Property, Southern British Columbia |
Globe Newswire |
07/28 |
07:00 |
| Selkirk Copper Mines Inc. Begins Trading on OTCQX Best Market |
Globe Newswire |
07/28 |
07:00 |
| Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder |
Globe Newswire |
07/28 |
07:00 |
| Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026 |
Globe Newswire |
07/28 |
07:00 |
| Lungpacer Announces Health Economic Analysis Demonstrating Clinical and Cost Benefits of AeroPace in Mechanically Ventilated Patients |
Globe Newswire |
07/28 |
07:00 |
| Antag Therapeutics Announces Dosing of First Patient in Phase 2a Trial of First-in-Class GIPR Antagonist AT7687 |
Globe Newswire |
07/28 |
07:00 |
| Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML |
Globe Newswire |
07/28 |
07:00 |
| Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026 |
Globe Newswire |
07/28 |
07:00 |
| Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus |
Globe Newswire |
07/28 |
07:00 |
